Keyword: upadacitinib (ABT-494)
ICER is still concerned about high prices of next-generation RA drugs—a stance that's not going over well among RA drugmakers and patient groups.
With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly.
AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?
AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication.
Painted as the follow-up drug to Humira, AbbVie’s JAK med Rinvoq has blockbuster hopes in mind. An early nod in the EU could help it reach that goal.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
Just days after releasing a report suggesting that three JAK inhibitors for rheumatoid arthritis wouldn't be cost-effective, ICER is backtracking.
JAK inhibitors to treat rheumatoid arthritis, like AbbVie's Humira follow-up, Rinvoq, may not be cost effective, ICER says in a new report.
JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.